Three labs launch iPS Parkinson’s study

C

Claire

New member
Three labs launch iPS Parkinson’s study


11:45 pm, July 25, 2015

Jiji Press OSAKA (Jiji Press) — Sumitomo Dainippon Pharma Co. , Hitachi Ltd. and a Kyoto University research team said Friday they have launched joint research on the clinical application of a Parkinson’s disease treatment technology based on induced pluripotent stem, or iPS, cells.

The three participants aim for the clinical application after 2016.

The project is sponsored by the Economy, Trade and Industry Ministry and the Japan Agency for Medical Research and Development.

According to Sumitomo Dainippon Pharma, Parkinson’s disease affects 100 to 150 of every 100,000 people. The disease is caused by a lack of dopamine, an essential substance in the human brain, the company said. In the joint research, the three entities hope to use iPS cells to produce cells that emit dopamine, and transplant them to Parkinson’s disease sufferers.

Sumitomo Dainippon Pharma and the Center for iPS Cell Research and Application at Kyoto University will be in charge of the analysis and evaluation of procedures to culture iPS cells. Hitachi will work with Sumitomo Dainippon Pharma on improving automatic cell-culturing equipment.Speech
 
C

Claire

New member
Japan continues to leave the US in the dust due to the FDA's arbitrary and nonsensical regulation of our own stem cells as pharmaceutical drugs.
 
B

barbara

Pioneer Founding member
I completely agree. The U.S. problem is also compounded by those with their own interests who feed continually at the grant trough. As far as I know, there is just one trial with only 8 patients that will be conducted in the future (not sure what year) here in the U.S. It is patient funded. Another big difference is that in Japan the whole country is working together as a team to bring cures to patients.


This article sounds like patients will be getting treated in Japan by next year once production is worked out.

http://www.biospectrumasia.com/biospectrum/news/221982/three-major-japanese-labs-collaborate-parkinson-s-disease-research

The three organizations have agreed to work together to develop the base technology and the evaluation methods for establishing a production process of dopaminergic neural progenitor cells Tokyo: Sumitomo Dainippon Pharma Co. Ltd., Center for iPS Cell Research and Application, Kyoto University (CiRA) and Hitachi Ltd. have signed a collaborative research program based on induced pluripotent stem cells, or iPS cells, for the treatment of Parkinson's disease.

It is a government sponsored program for which grant was awarded to the organizations by the Ministry of Economy, Trade and Industry and The Japan Agency for Medical Research and Development for the fiscal year 2015. CiRA and Sumitomo Dainippon Pharma have been engaged in a joint research with a view to developing a clinical treatment of patients with Parkinson's disease by the use of human iPS cells. Hitachi, meanwhile, has promoted development of an automatic cell culturing technology. The three organizations have agreed to work together to develop the base technology and the evaluation methods for establishing a production process of dopaminergic neural progenitor cells with a view toward clinical application of human iPS cell-based regenerative medicine technology for patients with Parkinson's disease.

The objective of the joint program is to establish a production method which would enable efficient mass-production and stable supply of safe and consistent quality cells.
 
You must log in or register to reply here.
Top